prikaz prve stranice dokumenta Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
  Preuzmi
PDF 277.9 KB
Stručni rad - Ostalo
Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
Journal of Infection, 86 (2023), 1; 66-117. https://doi.org/10.1016/j.jinf.2022.10.030
Marčec, Robert; Dodig, Vinko Michael; Likić, Robert

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Marčec, R., Dodig, V. M. i Likić, R. (2023). Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?. Journal of Infection, 86. (1), 66-117. doi: 10.1016/j.jinf.2022.10.030

Marčec, Robert, et al. "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?." Journal of Infection, vol. 86, br. 1, 2023, str. 66-117. https://doi.org/10.1016/j.jinf.2022.10.030

Marčec, Robert, Vinko Michael Dodig i Robert Likić. "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?." Journal of Infection 86, br. 1 (2023): 66-117. https://doi.org/10.1016/j.jinf.2022.10.030

Marčec, R., Dodig, V. M. i Likić, R. (2023) 'Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?', Journal of Infection, 86(1), str. 66-117. doi: 10.1016/j.jinf.2022.10.030

Marčec R, Dodig VM, Likić R. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?. Journal of Infection [Internet]. 01.2023. [pristupljeno 06.05.2024.];86(1):66-117. doi: 10.1016/j.jinf.2022.10.030

R. Marčec, V. M. Dodig i R. Likić, "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?", Journal of Infection, vol. 86, br. 1, str. 66-117, Siječanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:888007. [Citirano: 06.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:888007
Podaci o radu
Naslov (engleski)Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
AutorRobert Marčec
AutorVinko Michael Dodig
AutorRobert Likić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeStručni rad - Ostalo
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Infection
Brojčani podacivol. 86, br. 1, str. 66-117
p-ISSN0163-4453
DOIhttps://doi.org/10.1016/j.jinf.2022.10.030
URN:NBNurn:nbn:hr:105:888007
Datum objave publikacije2023-01
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0163445322006272
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-07-14 08:55:55